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ABSTRACT
Allogeneic hematopoietic stem cell transplantation (HSCT) is established therapy for selected patients
with acute leukemia. After transplantation, antileukemic immune responses are believed to eliminate
residual leukemia cells and decrease the likelihood of relapse. However, the clinical effect of successful
antigen-specific immune reconstitution after HSCT on the likelihood of leukemic relapse and overall survival
is not known. Pediatric recipients of unrelated cord blood transplants who underwent transplantation for
acute leukemia were sequentially evaluated for their development of antigen-specific T-lymphocyte
immunity to herpes viruses. The clinical effect of a positive antigen-specific response on relapse-free
survival was determined. The presence of an antigen-specific response resulted in a relapse-free survival
advantage (P  .0001), which was primarily due to a decrease in leukemic relapse (P  .003). Proportional
hazards modeling for time to relapse and time to relapse or death defined 3 variables that were strongly
associated with a poor outcome: female gender, poor remission status before transplantation, and negative
antigen-specific T-lymphocyte proliferation. Notably neither acute nor chronic graft-versus-host disease
had any effect on the incidence of leukemic relapse. Successful antigen-specific immune reconstitution
after unrelated cord blood transplantation results in decreased leukemic relapse and improved overall
survival.
© 2006 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Relapse is a major cause of failure after histo-
ompatible hematopoietic stem cell transplantation
HSCT) for acute leukemia when using bone mar-
ow (BM) or peripheral blood stem cells (PBSCs)
1,2]. When unrelated donors are used, the inci-
ence of leukemic relapse is decreased, but there is
o overall improvement in relapse-free survival
RFS) because of increased mortality due to graft-
ersus-host disease (GVHD) and its complications
3,4]. If adequate antigen-speciﬁc immune function
s present, the new donor-derived immune system aas the potential to decrease leukemic relapse and
nfectious deaths. Because of the confounding ef-
ects of GVHD, it has been difﬁcult to determine
he effect of successful immune reconstitution on
eukemic relapse and RFS. Patients who undergo
nrelated cord blood transplantation (UCBT) have
decreased incidence of GVHD compared with
atients who received unrelated BM or PBSC trans-
lants [5,6]. Therefore, the clinical effect of the
evelopment of antigen-speciﬁc T-lymphocyte im-
unity on leukemic relapse and RFS was evaluatedfter UCBT.
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tudy Population
The Cord Blood Transplant (COBLT) study
roup is a multi-institutional phase II trial of UCBT
ponsored by the National Heart, Lung and Blood
nstitute of the National Institutes of Health. The
ransplantation protocol was approved by the institu-
ional review board of each participating institution.
ll legal guardians were required to give written in-
ormed consent before subject enrollment. Pediatric
atients (18 years old) with acute lymphoblastic leu-
emia (ALL) or acute myelogenous leukemia (AML)
nderwent transplantation after preparation with trial-
esignated preparative regimes. Patients, other than
hose diagnosed with infant leukemia, were conditioned
ith total body irradiation (9 fractions of 150 cGy) given
wice daily on days 8 to 4; cyclophosphamide 60
g/kg on days 3 and 2; and antithymocyte glob-
lin (equine) 30 mg/kg/d on days3 through1 with
ethylprednisolone 2 mg · kg1 · d1. Patients diag-
osed with infant leukemia received oral busulfan
20-40 mg/m2/dose with dosing based on patient age
ith pharmacokinetic dose adjustment) or intravenous
usulfex (0.8-1.0 mg/kg with dosing based on patient
ge) for 16 doses on days 8 through 5 and mel-
halan 45 mg/m2 on days4 through2, rather than
otal body irradiation. On the day of transplantation,
atients received 2 doses of methylprednisolone 1
g/kg, with 1 dose given just before the infusion of
he UCB unit. GVHD prophylaxis consisted of meth-
lprednisolone 0.5 mg/kg/d twice daily on days 1
hrough 4 and then 1 mg/kg twice daily on days 5
o 19 or until the ﬁrst day the absolute neutrophil
ount reached 500/mm3, at which time the dose was
apered at the rate of 0.2 mg · kg1 · wk1. Cyclo-
porine was begun on day3 and continued to at least
ay 180, when the dose was tapered at the rate of 5%
er week of the initial dose if the recipients had no
vidence of GVHD.
Each patient underwent transplantation with only
UCB unit. Initial HLA typing was done by low/
ntermediate molecular typing for HLA-A and
LA-B alleles and high resolution molecular typing
or HLA-DRB1. Eligibility criteria initially required
t least a 4 of 6 match or a 3 of 6 match if the match
as based on high resolution molecular typing for
LA-A, -B, and -DRB1. Most patients (110 of 117)
ho were initially tested with low/intermediate mo-
ecular typing were retrospectively re-typed with high
esolution molecular typing for HLA-A and HLA-B
lleles (ﬁnal HLA typing). For analysis purposes, the
nal HLA typing was used.
The presence of prior infection with herpes vi-
uses (cytomegalovirus [CMV], varicella zoster virus
VZV], and herpes simplex virus [HSV]) was deter-
ined by pretransplantation serology in the clinical taboratories of the transplantation institution. Surveil-
ance for CMV reactivation after transplantation was
one according to institutional policy; CMV anti-
ody-negative recipients received CMV-negative or
eukocyte-depleted blood products. CMV-positive re-
ipients were permitted to receive prophylaxis with
anciclovir until day 100 once their absolute neu-
rophil count reached 750/mm3 for 2 days. Recipients
ith detectable CMV reactivation were preemptively
reated per institutional policy. HSV-positive recipi-
nts could receive acyclovir as prophylaxis. Pneumocys-
is carinii prophylaxis, fungal prophylaxis, and intrave-
ous immunoglobulin were administered according to
nstitutional practice. Clinically signiﬁcant infections
nd their causative organisms were recorded, as were
he causes of death. All data were retrospectively re-
iewed centrally for accuracy. Treatment-related
ortality included deaths due to veno-occlusive dis-
ase and idiopathic interstitial pneumonitis.
Recipients who were in ﬁrst or second complete
emission before transplantation were considered to
e in a good remission status, whereas recipients in
hird complete remission or greater, relapse, or induc-
ion failure were considered to be in a poor remission
tatus.
ssessment of Immune Reconstitution
Peripheral blood from UCB transplant recipients
as collected in preservative-free heparin 1, 2, 3, 6, 9,
2, 18, 24, and 36 months after transplantation. Spec-
mens were transported overnight to the Childrens
ospital Los Angeles for central evaluation of immu-
ophenotype and antigen-speciﬁc T-lymphocyte pro-
iferation. Whole blood specimens were analyzed for
ercentages and absolute numbers of CD3; CD4;
D8; CD19; CD4, CD45RA; CD4, CD45RO; and
D56 expressing leukocytes using 3-color immuno-
uorescence and ﬂuorescence-activated cell sorting
nalysis by previously published methods [7]. Brieﬂy,
amples were stained with the appropriate ﬂuorescent-
abeled monoclonal antibodies and the percentage of
ositive cells was determined after gating on the iso-
ype control. Absolute numbers of cells were calcu-
ated by multiplying the peripheral white blood cell
ount by the percentage of positive cells.
Antigen-speciﬁc T-lymphocyte proliferation was
etermined in all samples with adequate cell numbers.
ononuclear cells were isolated on discontinuous
radients (Ficoll-Hypaque, Ficoll 1.077, Pharmacia-
KB Biotechnology, Piscataway, NJ). The interface
ells were collected, washed, and suspended at 5 105
ells/mL in RPMI 1640 medium with 10% heat-acti-
ated human A serum, glutamine, and antibodies. In
ddition, 1  105 cells (0.2 mL) was added to U-
ottom microtiter wells, and their optimal concentra-
ions of herpes virus antigen were added. Frozen ly-
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Immune Reconstitution and Leukemic Relapse 921ates of CMV-, HSV-, and VZV-infected ﬁbroblasts
ere obtained from Dr M. Levin (University of Col-
rado, Denver). Assays were performed in triplicate.
ntigen-stimulated cultures were pulsed with triti-
ted thymidine (1 Ci/well) on day 6. After 18
ours, cells from the stimulated and control wells
ere harvested, and the incorporated radioactivity
as determined. Increases in counts per minute
3000 (mean of stimulated cells minus mean of
ontrol cells) were considered positive for the anti-
en-stimulated cultures [8]. Recipients who developed
positive antigen-speciﬁc proliferative response at any
ime during the 3-year observation period were con-
idered positive, whereas recipients who never devel-
ped positive proliferative responses were considered
egative.
tatistical Considerations
Time to relapse was deﬁned as the time to the
rst observation of hematologic or cytogenetic
hanges characteristic of leukemic relapse. Relapse
as diagnosed when leukemic blasts were docu-
ented in the blood or marrow (5%) or extramed-
llary site. All calculations were done with SAS 8.2
SAS Institute, Cary, NC). Tests of difference in
umulative incidence of relapse or RFS were per-
ormed with the log-rank test. Proportional hazards
odeling of factors possibly inﬂuencing time to
elapse or death was performed by using different
odel selection methods including backward and
orward selections. P  .01 was considered statisti-
ally signiﬁcant. The P values, hazard ratios, and
onﬁdence intervals of the signiﬁcant factors varied
ittle by selection technique and were similar with
o selection. In modeling time to relapse, deaths
ithout relapse were censored. Acute GVHD was
reated as a binary factor split as 0-I versus II-IV or
-II versus III-IV. Models that treated acute and
hronic GVHD as time-dependent covariates were
lso considered.
able 1. Immunophenotypic Analysis of Peripheral Blood Leukocytes of
Months After
Transplantation
CD3† CD4†
n* Mean SD Mean SD
0-3 194 131 165 66 87
3-6 135 360 493 155 172
6-12 122 894 1148 475 565
12-24 65 1722 1026 1071 613
>24 35 2182 918 1302 561
Normals‡ 2300 1300
Number of evaluations performed.
Cells per cubic millimeter.
Two to ﬁve years old [36].ESULTS
tudy Patients
One hundred seventeen patients with ALL (n 
8) or AML (n 39) were evaluated for their antigen-
peciﬁc immune function after UCBT. Three hun-
red nine assays of antigen-speciﬁc T-lymphocyte
roliferation to herpes viruses were performed. Thirty-
our recipients were evaluated once, 28 recipients
wice, 22 recipients 3 times, and 33 recipients 4
imes. If adequate peripheral blood leukocytes were
resent, all recipients were tested at all time points.
mmunophenotypic Evaluation of Immune
econstitution
Peripheral blood leukocytes from all 117 recipi-
nts were evaluated by ﬂow cytometry. The kinetics of
-lymphocyte (CD3, CD4, and CD8), B-lymphocyte
CD19), natural killer cell (CD56), and naive T-lym-
hocyte (CD4 and CD45RA) reconstitution are pre-
ented in Table 1. The association of multiple possible
iological variables with the kinetics of immune re-
onstitution was evaluated. Most variables (GVHD
tatus, pretransplantation remission status, cell dose
er kilogram, CD34 cell dose per kilogram, recipient
ge, Lansky score) had no association with the kinetics
f immune reconstitution. The only signiﬁcant asso-
iation was between HLA mismatch and decreased
D4 counts at3 months. At other time points, HLA
atch had no signiﬁcant association with the kinetics
f immune reconstitution.
ntigen-Specific T-Lymphocyte Responses
o Herpes Viruses
Protection against viral and fungal pathogens cor-
elates with antigen-speciﬁc T-lymphocyte function
nd not with the presence of immunophenotypic T
ymphocytes. Therefore, to determine whether UCB
ransplant recipients had achieved antigen-speciﬁc im-
une reconstitution, we chose to evaluate sequentially
he proliferative responses of recipient T lymphocytes
o a clinically relevant group of pathogens, ie, the
ransplant Recipients for Acute Leukemia
D8† CD4,CD45RA† CD19† CD56†
SD Mean SD Mean SD Mean SD
125 16 84 9 33 264 277
380 22 92 162 356 468 370
779 170 312 547 583 401 427
483 729 636 943 763 264 263
403 908 593 1035 774 363 529
900 800 400UCB T
C
Mean
65
196
429
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783
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R. Parkman et al.922erpes viruses CMV, HSV, and VZV. Most recipients
ere serologically assessed before transplantation to
ssess prior herpes virus exposure. Of the 117 recipi-
nts, 86 had been infected with1 herpes virus before
ransplantation, whereas 15 were negative for all 3
iruses. Data were not available from 16 recipients.
A positive antigen-speciﬁc T-lymphocyte re-
ponse was considered to be an increase in counts per
inute 3000 (mean of stimulated cells minus mean
f control cells), which represents a stimulation index
7. The earliest positive proliferative response was
etected 29 days after transplantation to HSV. Of the 48
able 2. Characteristics of 117 Acute Leukemic Patients Who Underw
roliferative Responses
Neg
atient related
Age, y
Median
Range
Sex, n (%)
Male
Female
Lansky score, n (%)
<80
>80
isease related
Primary disease
AML, n (%)
CR1
CR2
>CR3/relapsed/induction failure
ALL, n (%)
CR1
CR2
>CR3/relapsed/induction failure
Remission status (ALL  AML), n (%)
Good (CR1  CR2)
Poor (CR3/relapsed/induction failure)
Length of CR1 (ALL  AML)
Median (days)
Cytogenetic risk status (ALL  AML), n (%)
Good
Poor
ransplantation related
HLA (final typing), n (%)
<4/6
>5/6
Conditioning regimen, n (%)
Busulfan/melphalan
TBI/cyclophosphamide
Acute GVHD (reviewed grade), n (%)
<1
>2
Chronic GVHD, n (%)
No
Yes
Cell dose, cells/kg  107
Median
RangeR1 indicates ﬁrst complete remission; CR2, second complete remission;ecipients with positive proliferative responses during
he ﬁrst 3 years after HSCT, 36 developed responses to
ZV, 29 to HSV, and 25 to CMV. Twenty-one re-
ipients developed responses to only 1 virus, 12 to 2
iruses, and 15 to all 3 viruses.
The clinical characteristics of the UCB transplant
ecipients with and without positive proliferative re-
ponses to the herpes viruses are presented in Table 2.
he 2 populations did not differ signiﬁcantly in terms
f patient age, sex, performance status, cell dose, dis-
ase type, length of ﬁrst complete remission, poor-risk
ytogenetics, HLA disparity, and acute or chronic
BT and Were Assessed for Anti-Herpes Virus T-Lymphocyte
Antigen-Specific Response
n  69) Positive (n  48) All (n  117)
8.2 6.7
7.0 0.6-17.9 0.6-17.9
8) 33 (69) 73 (62)
2) 15 (31) 44 (38)
4) 6 (13) 16 (14)
6) 42 (88) 101 (86)
3) 16 (33) 39 (33)
7) 5 (31) 9 (23)
8) 6 (38) 17 (44)
5) 5 (31) 13 (33)
7) 32 (67) 78 (67)
3) 6 (19) 12 (15)
9) 19 (59) 46 (59)
8) 7 (22) 20 (26)
0) 36 (75) 84 (72)
0) 12 (25) 33 (28)
303 318
0) 40 (83) 95 (81)
0) 8 (17) 22 (19)
7) 26 (54) 72 (63)
3) 22 (46) 45 (37)
6) 7 (15) 18 (15)
4) 41 (85) 99 (85)
1) 28 (58) 70 (62)
9) 20 (42) 46 (38)
4) 37 (77) 81 (69)
6) 11 (23) 36 (31)
6.0 6.0
3.7 2.1-20.4 1.4-23.7ent UC
ative (
5.8
0.6-1
40 (5
29 (4
10 (1
59 (8
23 (3
4 (1
11 (4
8 (3
46 (6
6 (1
27 (5
13 (2
48 (7
21 (3
333
55 (8
14 (2
46 (6
23 (3
11 (1
58 (8
42 (6
26 (3
44 (6
25 (3
6.2
1.4-2CR3, third complete remission; TBI, total body irradiation.
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Immune Reconstitution and Leukemic Relapse 923VHD status. In addition, no association was de-
ected between immunophenotype (CD3, CD4, CD8,
r CD4, CD45RA) and the presence or absence of an
ntigen-speciﬁc proliferative response (Table 3).
linical Effect of a Positive Antiviral Response
To determine the clinical effect of the develop-
ent of an antigen-speciﬁc T-lymphocyte response,
he RFS of recipients with and without positive anti-
en-speciﬁc responses was determined (Figure 1). Re-
ipients with a positive response had a survival advan-
age (P  .0001).
The events (relapse and death) of recipients with
nd without positive proliferative responses were re-
iewed (Table 4). Although there was a trend toward
ewer deaths from infection in recipients with a posi-
ive proliferative response (P  .04), the chief cause
or the observed difference in RFS between the posi-
ively and negatively responding recipients was the
ecreased incidence of leukemic relapse (23 relapses in
9 recipients with negative responses versus 8 relapses
n 48 recipients with positive responses).
The cumulative incidence of acute leukemic re-
apse is shown in Figure 2. Recipients with a negative
ntigen-speciﬁc proliferative response to the herpes
iruses were signiﬁcantly more likely to relapse than
ere recipients with a positive response (P .003). Of
he 23 AML recipients without a proliferative re-
ponse, 10 relapsed, whereas only 2 of 16 recipients
ith a positive proliferative response relapsed. Of the
6 ALL recipients without an antigen-speciﬁc prolif-
rative response, 13 recipients relapsed, whereas 6 of
2 recipients with a positive proliferative response
elapsed.
roportional Hazards Analysis
To evaluate the effect of competing variables on
he likelihood of leukemic relapse and RFS in recipi-
nts, proportional hazards regression models for time
o relapse and time to relapse or death were evaluated.
able 3. Impact of Immunophenotype on Development of Antigen-
peciﬁc T-Lymphocyte Proliferation After UCBT
Months After
Transplantation
Antigen-Specific Proliferation*
Positive Negative P
1 38 48 .21
2 40 46 .25
3 43 61 .44
6 39 37 .20
12 37 31 .45
18-24 28 13 .14
Number of samples assayed. Hotelling’s T test of comparing mean
counts of CD3, CD4, CD8, and CD4,CD45RA cells in each
period between samples that had positive and negative antigen-
speciﬁc proliferative responses to 1 herpes virus.hen using all the variables presented in Table 2 andretransplantation serostatus for CMV, female gender
hazard ratio [HR], 6.6; P  .0001), poor (third com-
lete remission, relapse, or induction failure) pretrans-
lantation remission status (HR, 3.6; P  .001), a
egative antigen-speciﬁc proliferative response (HR,
.7; P  .003), and a poor performance status (HR,
.4; P  .007) were strongly associated with an in-
reased likelihood of leukemic relapse. Importantly,
igure 1. Probability of relapse-free survival by antigen-speciﬁc
egative (dotted line) and positive (solid line) proliferative response
tatus. Censored observations are denoted by vertical lines. P 
0001, log-rank test for difference between curves.
able 4. Causes of Death/Relapse by Antigen-Speciﬁc Proliferative
esponse Status*
Negative (n  69) Positive (n  48)
elapse 21 8
RM 4 0
cute GVHD 1 1
hronic GVHD 2 2
nfection 10 1
Viral 5 1
Fungal 3 0
Bacterial 1 0
Other 1 0
otal (relapse or death) 38 12
RM indicates treatment-related mortality.
Comparison of proportion of infectious deaths (10/69 versus 1/48)gives P  0.04 when using 2-sided Fisher exact test.
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R. Parkman et al.924either acute nor chronic GVHD on a time-depen-
ent or maximal grade basis had any effect on the
ikelihood of leukemic relapse (Table 5).
When RFS was modeled, 3 of the same vari-
bles, ie, recipient gender (HR, 2.5; P  .0003),
retransplantation remission status (HR, 2.4; P 
004), and a negative proliferative response (HR,
.6; P  .0002), remained highly signiﬁcant. Nei-
her acute nor chronic GVHD status had any sig-
iﬁcant effect, whether or not they were modeled as
ime-dependent covariates.
ISCUSSION
The reconstitution of the recipient immune sys-
em after HSCT has a signiﬁcant effect on clinical
utcome [9-12]. HSC transplant recipients have an
mmune deﬁciency of varying severity and duration
hat predisposes them to opportunistic infections and
otentially death. The donor T lymphocytes infused
s part of the HSCT inoculum contribute to the
ascade of events that results in acute and chronic
VHD [13,14]. The donor-derived immune system
ay also provide a graft-versus-tumor effect against
esidual recipient tumor cells, especially lymphohema-
opoietic malignancies [15,16]. After unrelated
SCT, an increased incidence of acute and chronic
VHD occurs, which in some studies results in a
ecrease in the incidence of leukemic relapse but no
verall improvement in survival due to more infec-
igure 2. Cumulative incidence of leukemic relapse by positive
solid line) or negative (dotted line) proliferative response status.
 .003, log-rank test for difference between curves.ious and transplant-related deaths [15,17,18]. Be-ause of the competing negative effects of GVHD, it
as not been possible to determine the singular effect
f the successful reconstitution of the recipient im-
une system on leukemic relapse or infectious deaths.
Successful recipient immune reconstitution re-
uires the development of antigen-speciﬁc immune
unction by cells derived from the HSC and naïve T
ymphocytes contained in the transplant innoculum.
he presence of donor-derived antigen-speciﬁc T
ymphocytes in the recipient does not represent
uccessful immune reconstitution. Since cord blood
ontains no antigen-speciﬁc T lymphocytes, we at-
empted to determine whether successful antigen-spe-
iﬁc immune reconstitution with the potential for im-
une responses to both infectious pathogens and
eukemic cells would result in improved RFS. In the
resent study, we have demonstrated the positive clin-
cal impact of successful immune reconstitution (as
easured by the development of antigen-speciﬁc T
ymphocyte proliferative responses to one or more
erpes viruses) on both the incidence of leukemic
elapse and RFS. One reason for our detection of the
ositive impact of successful immune reconstitution is
he lack of acute GVHD as a confounding variable. In
he present study, neither acute nor chronic GVHD
as associated with a reduction in the likelihood of
eukemic relapse. Chronic GVHD has been shown to
ave a signiﬁcant graft-versus-leukemia (GVL) effect
n previous studies of histocompatible and unrelated
M transplant recipients [15].
able 5. Proportional Hazards Regression Models for Time to Relapse
nd Time to Relapse or Death for Recipients With Acute Leukemia
Variable Hazard Ratio (95% CL) P
ime to relapse
Gender
Female 6.6 (2.8, 15.5) .0001
Male 1
Remission status
Worse than CR2 3.6 (1.6, 7.8) .001
CR1 or CR2 1
Proliferative response
Negative 3.7 (1.6, 8.5) .003
Positive 1
Performance status
<80 3.4 (1.4, 8.4) .007
>80 1
ime to relapse or death
Gender
Female 2.9 (1.6, 5.2) .0003
Male 1
Remission status
Worse than CR2 2.4 (1.3, 4.4) .004
CR1 or CR2 1
Proliferative response
Negative 3.6 (1.8, 7.0) .0002
Positive 1
L indicates conﬁdence limit; CR1, ﬁrst complete remission; CR2,
second complete remission; CR3, third complete remission.
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Immune Reconstitution and Leukemic Relapse 925The presence of antigen-speciﬁc T-lymphocyte
mmunity requires a competent immune system and a
timulating antigen. We chose to evaluate the T-
ymphocyte responses to a clinically relevant group of
athogens, the herpes viruses (CMV, HSV, and
ZV). Most herpes virus infections soon after HSCT
re due to reactivation of herpes viruses present before
ransplantation, whereas later infections may be due to
cquisition of the virus after HSCT [19]. Among the
01 recipients in the present study whose pretrans-
lantaiton serology was evaluated, 85% were positive
efore transplantation for 1 herpes virus and 15%
ere negative. Thus, most recipients had the potential
or herpes virus reactivation and, therefore, antigenic
timulation.
Because the time of viral reactivation is undetect-
ble in many recipients, the lack of an antigen-speciﬁc
esponse at any particular time point does not mean
hat there is a lack of successful immune reconstitu-
ion at that time point because the lack of a positive
ntigen-speciﬁc response may be due to the lack of
ntigenic stimulation. However, by studying UCB
ransplant recipients for 3 years, we believe that most
ecipients will have reactivated 1 of their pretrans-
lantation viruses or will have been exposed to exog-
nous herpes viruses in the case of recipients who were
eronegative before UCBT. Thus, during the obser-
ation period, the development of a positive antigen-
peciﬁc proliferative response to a clinically signiﬁcant
ntigen documents successful immune reconstitution,
hereas recipients without proliferative responses
ay lack successful immune reconstitution. Of note is
hat 6 of the 15 recipients without pretransplantation
erpes virus infections developed positive responses,
resumably due to exogenous viral infection after
ransplantation.
The most powerful association of the presence of
n antigen-speciﬁc proliferative response was the de-
rease in the incidence of relapse in recipients with
cute leukemia (Figure 2; P  .003). The cellular
echanisms of the GVL effect are a topic of contro-
ersy [20,21]. Based on clinical and animal studies,
VHD can kill normal and leukemic recipient cells
hat share major or minor histocompatibility antigens
22,23]. In other cases, T lymphocytes speciﬁc for
ntigens uniquely expressed or overexpressed on leu-
emia cells (bcr/abl, proteinase-3) have been identiﬁed
24,25]. The documentation that donor-recipient
iller cell immunoglobulin-like receptor mismatches
an decrease the incidence of AML but not of ALL
elapse after T-cell–depleted haploidentical trans-
lantation suggests a role for natural killer cells in the
VL effect against AML [26]. Thus, the successful
econstitution of the recipient immune system may
esult in a decrease in leukemic relapse by multiple
ellular mechanisms depending on the recipient’s pri-
ary disease. Further, recipients with positive re- bponses had fewer deaths due to infection (10 infec-
ious deaths in 69 negative recipients versus 1 death in
8 positive recipients).
We examined if it were possible to determine
mmunophenotypic characteristics that would predict/
orrelate with the development of the antigen-speciﬁc
-lymphocyte responses to the herpes viruses. Exten-
ive analysis of CD3, CD4, and CD8 counts (Table 3),
heir kinetics, and counts higher and lower than the
ean demonstrated no correlation with the presence
r absence of antigen-speciﬁc responses (data not
hown). Another possibility was that recipients with-
ut positive proliferative responses had defects in thy-
opoiesis after UCBT, which limited the production
f new T lymphocytes from the engrafted donor HSC
27,28]. The present study was initiated before the
eneral availability of the T-cell excision circle anal-
sis to evaluate thymopoiesis [29]. Thus, we enumer-
ted CD4, CD45RA-positive T lymphocytes to mea-
ure recipient thymopoiesis [30]. No difference in the
inetics of the recovery of CD4, CD45RA T lympho-
ytes was seen in recipients with and without the
evelopment of positive proliferative responses. Thus,
one of the present immunophenotypic assays could
redict which recipients would develop successful an-
igen-speciﬁc immune reconstitution. Previous studies
valuating immune reconstitution after HSCT and
CBT have focused on immunophenotypic analyses
nd not on the assessment of antigen-speciﬁc T-lym-
hocyte function [31,32]. Because in the present study
he immunophenotypic assays did not predict antigen-
peciﬁc function, the previous studies may not have
een able to demonstrate the positive effect of suc-
essful immune reconstitution on the likelihood of
eukemic relapse or RFS because they did not measure
ntigen-speciﬁc function.
After transplantation with BM, recipients are in-
used with mature antigen-speciﬁc and naive donor T
ymphocytes, making the evaluation of the origin of
ntigen-speciﬁc function after transplantation difﬁcult
f antigens to which the donor was immune, such as
he herpes viruses and tetanus toxoid, are used to
valuate immune reconstitution. Thus, soon after
ransplantation it is difﬁcult to determine whether the
ntigen-speciﬁc T lymphocytes identiﬁed are derived
rom mature antigen-speciﬁc T lymphocytes con-
ained in the HSC inoculum. In the present study, the
lymphocytes contained in the cord blood unit were
aive and did not have preexisting immunity to the
erpes viruses. Therefore, if antigen-speciﬁc T-lym-
hocyte responses to herpes viruses were detected
fter UCBT, the response represented successful im-
une reconstitution and was not due to infused do-
or-derived antigen-speciﬁc T lymphocytes. One
trategy to evaluate the recipients of BM or PBSCs for
he effect of successful immune reconstitution would
e the use of timed immunizations after transplanta-
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R. Parkman et al.926ion with a neoantigen such as keyhole limpet hemo-
yanin, to which the donor were not immune, to
etermine when successful immune reconstitution oc-
urs [33]. Future prospective studies using such a
trategy should be undertaken to conﬁrm and extend
he observations of the present study.
The present study could not determine the effect
f the time of development of antigen-speciﬁc func-
ion on the likelihood of leukemic relapse because the
ime of antigenic stimulation is unknown in most
ecipients. Prospective studies with timed immuniza-
ion with neoantigens will be necessary to evaluate the
ffect of the time of successful immune reconstitution
n the likelihood of leukemic relapse.
At present it is not clear what the biological dif-
erence is between the recipients who developed an-
igen-speciﬁc T-lymphocyte function and those who
id not. Activation-induced apoptosis has been re-
orted after HSCT and may contribute to the selec-
ive elimination of T lymphocytes activated by infec-
ious or leukemic antigens [34,35].
In addition to the absence of antigen-speciﬁc im-
une function, recipient female gender had a signif-
cant negative effect on RFS and leukemic relapse.
he frequency of the development of a positive im-
une response was independent of recipient sex so
hat the basis for the effect of recipient, but not of
onor, sex on the observed outcomes of present study
s unknown.
The demonstration of the positive clinical effect of
uccessful antigen-speciﬁc immune reconstitution af-
er UCBT on the incidence of leukemic relapse and
verall survival may only be possible because of the
ecreased severity of acute GVHD in UCB transplant
ecipients. The present results suggest that successful
ntigen-speciﬁc immune reconstitution may also have
positive clinical effect in the recipients of BM or
BSC, but that the beneﬁts may be difﬁcult to dem-
nstrate because of the competing negative effects of
VHD. Further clinical research should be directed
t prospective studies of the effect of the development
f antigen-speciﬁc immune function after neoantigen
mmunization and improving the immune reconstitu-
ion of HSC transplant recipients with documented
efects in antigen-speciﬁc T-lymphocyte function.
he successful immune reconstitution of such recipi-
nts may result in a decreased incidence of leukemic
elapse and death, resulting in improved survival of
SC transplant recipients.
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